MM1YA-CTG01 A Measurable Residual Disease (MRD) Focused, Phase II Study Of Venetoclax Plus Chemotherapy For Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 Myelomatch Clinical Trial
Objective
Primary Objective: To compare the rates of undetectable measurable residual disease (MRD) in patients who achieve a Complete Remission (CR) after induction therapy with 7 +3 (cytarabine + daunorubicin) vs. azacitidine + venetoclax vs. 7+3 + venetoclax.
Secondary Objective: To estimate the frequency and severity of toxicities with each of the regimens. To estimate complete remission (CR) rates (with and without MRD), complete remission with incomplete count recovery (CRi) (with and without MRD) rates, event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) with each of the regimens.
